All In Biotech

Drug Trial Radar · NCT03895203

A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active Reference (Adalimumab) Study Evaluating the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 852 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

852

Actual

Start

Apr 3, 2019

Primary completion

Aug 17, 2021

Study completion Jul 11, 2022

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
Mar 29, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to demonstrate the clinical efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared with placebo in the treatment of subjects with active Psoriatic Arthritis (PsA).

Conditions

  • Psoriatic Arthritis

Interventions

  • BimekizumabDrug

    Subjects will receive bimekizumab at pre-specified time-points.

  • AdalimumabDrug

    Adalimumab will be administered according to the labeling recommendations.

  • PlaceboOther

    Subjects will receive placebo at pre-specified time-points.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With an American College of Rheumatology (ACR) 50 Response at Week 16Time frame: Week 16

Locations

136 sites in 14 countries. Site status is shown where the registry gives one.

  • Pa0010 50017

    Phoenix, Arizona

  • Pa0010 50035

    San Diego, California

  • Pa0010 50004

    Tustin, California

  • Pa0010 50033

    Palm Harbor, Florida

  • Pa0010 50037

    Tampa, Florida

  • Pa0010 50039

    Atlanta, Georgia

  • Pa0010 50028

    Lexington, Kentucky

  • Pa0010 50015

    Hagerstown, Maryland

  • Pa0010 50016

    St Louis, Missouri

  • Pa0010 50029

    Albuquerque, New Mexico

  • Pa0010 50010

    Brooklyn, New York

  • Pa0010 50125

    Charlotte, North Carolina

  • Pa0010 50040

    Dayton, Ohio

  • Pa0010 50020

    Duncansville, Pennsylvania

  • Pa0010 50006

    Wyomissing, Pennsylvania

  • Pa0010 50008

    Johnston, Rhode Island

  • Pa0010 50007

    Orangeburg, South Carolina

  • Pa0010 50001

    Jackson, Tennessee

  • Pa0010 50012

    Memphis, Tennessee

  • Pa0010 50002

    Austin, Texas

  • Pa0010 50049

    Corpus Christi, Texas

  • Pa0010 50051

    Houston, Texas

  • Pa0010 50036

    Mesquite, Texas

  • Pa0010 50009

    Waco, Texas

  • Pa0010 50050

    Beckley, West Virginia

  • Pa0010 30005

    Camberwell, Australia

  • Pa0010 30002

    Clayton, Australia

  • Pa0010 30008

    Hobart, Australia

  • Pa0010 30003

    Maroochydore, Australia

  • Pa0010 30007

    Victoria Park, Australia

  • Pa0010 30006

    Woodville, Australia

  • Pa0010 40003

    Genk, Belgium

  • Pa0010 40002

    Leuven, Belgium

  • Pa0010 40059

    Mons, Belgium

  • Pa0010 50041

    Québec, Canada

  • Pa0010 50042

    Rimouski, Canada

  • Pa0010 50043

    Sidney, Canada

  • Pa0010 50044

    Trois-Rivières, Canada

  • Pa0010 40061

    Brno, Czechia

  • Pa0010 40065

    Brno, Czechia

Showing 40 of 136 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.